CITELINE JAPAN

T
OJ
KA
YP
OA
N

TUESDAY, OCTOBER 22, 2024
PA L AC E H OT E L , TO K Y O

ENTRY GUIDEE N T RY D E A D L I N E : M O N DAY , J U L Y 1 5 , 2 0 2 4

ENTRY INQUIRIES:Natalia Kay, Senior Events Manager • E: natalia.kay@citeline.com
Yojiro Terauchi, Senior Marketing Manager E: yojiro.terauchi@citeline.com

www.citeline.com/awards/CitelineJapanAwards

Key date: Entry deadline: Monday, July 15, 2024

WHY ENTER
Now in their third year, the Citeline Japan Awards recognize andreward outstanding achievements and innovations in Japanesepharma and biotech, highlighting Japan’s integral role in the global life
sciences and healthcare market. These awards bring together leading
contributors to meet and network, discover new opportunities, andreflect on life-changing accomplishments made over the previous year.

Categories are diverse and wide-ranging, including Pharma Company of the Year, BestNew Drug Award, Best Contract Research Organization and Executive of the Year.

C AT E G O R I E SBEST CONTRACT RESEARCHORGANIZATIONBEST CONTRACT DEVELOPMENTMANUFACTURING ORGANIZATIONBEST NEW DRUG

Brought to you by Citeline, the Awards provide a unique and trusted platform to enable
innovation, growth and commercial success for your organization.

BIOTECH COMPANY OF THE YEAR

• Honor your organization’s outstanding contribution to the pharma and biotech
industry.

EXECUTIVE OF THE YEAR

• Showcase Japan’s pivotal role in driving innovation in the global healthcare market.
• Be recognized as one of Japan’s leading organizations, and a key contributor to theglobal life sciences and healthcare market.
• Reflect on the importance of your achievements, and share best practice withother thought leaders in pharma and biotech.

LICENSING DEAL OF THE YEARFINANCING DEAL OF THE YEARThe Citeline Japan Awards are free to enter. The closing date for entries is Monday,
July 15, 2024, and the qualifying period for submissions is July 1, 2023 - June 30, 2024.

PHARMA COMPANY OF THE YEAR

The judging process will take place in August/September 2024. The finalists will
be contacted in September and the winners announced at the Awards ceremonyon Tuesday, October 22, 2024.

LIFETIME ACHIEVEMENTBEST CONTRACTRESEARCHO R G A N I Z AT I O NThis Award is to recognize contract researchorganizations that provide full or specialist
services to their clients and which have anoffice or other base (but not necessarily ahead office) either in Japan or the Asia region,
including Australia.

Entrant companies must offer services in Japan, but theachievements listed in the entry form do not necessarily
have to be trials or services conducted in Japan (forexample, clinical trials conducted in China or Australia arealso eligible).
Judging will consider the quality and benefits of services
and relationships built with clients and will pay particularattention to innovative patient trial recruitment strategies
brought to the table.
To qualify, candidates must draw on their achievements inthe qualifying period (July 1, 2023-June 30, 2024).
To enter this category, please answer the following:•

What particular capabilities and strengths does the CRO
offer?

•BEST CONTRACTDEVELOPMENTMANUFACTURINGO R G A N I Z AT I O NThis Award is to recognize contractdevelopment manufacturing organizations
that provide full or specialist services to theirclients and which have an office or other base(but not necessarily a head office) either inJapan or the Asia region, including Australia.
Entrant companies must offer services in Japan, but theachievements listed in the entry form do not necessarily
have to be services or manufacturing conducted in Japan(for example, such activities conducted in Asia or Australia
are also eligible).
Judging will consider the quality and benefits of services
and relationships built with clients and will pay particularattention to innovative services or processes brought to thetable.
To qualify, candidates must draw on their achievements inthe qualifying period (July 1, 2023-June 30, 2024).
To enter this category, please answer the following:•

How has the company delivered results that exceed
sponsor/partner expectations?

What particular capabilities and strengths does the
CDMO offer?

••

What innovations in patient recruitment strategy has the
CRO brought to its partner?

How has the company delivered results that exceed
partner expectations?

••

How has it improved its performance, for example, in its
quality of data, timelines and transparency?

What innovations in services or manufacturing
techniques/approaches has the CDMO brought to its
partners?

•

What steps is the CRO taking towards improving thecollection and reporting of trial data, through newprocedures and systems such as electronic data capture,storage and platforms?

•

How has it improved performance, for example,
timelines, more efficient processes?

•

What steps is the CDMO taking towards improving its
services through new systems/processes, for example
which reduce resource/energy use or costs?

BEST NEWDRUG
The Best New Drug Award recognizes
excellence in pharmaceutical development.
In this category, the judges will be looking
for the small-molecule, biological, cell/gene therapy, digital therapeutic or vaccine
product approved in Japan during thequalifying period that represents the best
therapeutic advance in its area.
Any recently launched new product is eligible toenter as long as it was approved in its first indicationin Japan between July 1, 2023 - June 30, 2024.
(Generic and biosimilar products are not eligible.)
Entrants must have played a key role in thedevelopment of the nominated product, for example
as a sole licensee or co-developer responsible for clinical
trials and/or regulatory submissions, and all company
members of joint development or joint ventureagreements should be disclosed in the application.
To enter this category, please answer the following:• Brand and generic name, indication, company(ies)involved in its development (if more than one
company, please detail the relationship between
the parties).
• Date and market of approval and launch.
• Mechanism of action. How is this differentiatedfrom other products and how does it represent a
step forward?
• Outline evidence for clinical activity, for example
summary results from registrational clinical
trials. How does this translate into a meaningful
therapeutic benefit for patients and over other drugs?
• What is the potential market size of the candidate?

BIOTECHCOMPANY OF
THE YEAR
This award honors outstanding achievements
by biotech companies over the qualifying
period (July 1, 2023 - June 30, 2024). This could
be in terms of moving the business froman early stage to a more mature company,
signing a transformative deal, taking its firstor a major new product towards the market,
or raising significant new funds.
To enter this category, please provide the following
information:• The company’s most significant achievement
during the year.
• Accomplishments in terms of: bringing new
products closer to market; raising funds;
significant licensing or partnership deals;
evidence that management has been able to
make difficult decisions to progress the company
and its products; using proprietary science or
technologies for unmet medical needs; transition
from early stage to more mature company.

EXECUTIVE
OF THE YEAR
Designed to acknowledge excellence inleadership, the winner of this award will be
the executive who has exhibited exemplary
leadership throughout the qualifying period(July 1, 2023 - June 30, 2024). Also importantto the judges will be the executive’s careerachievements, influence within the industry
and characteristics that make a good leader,such as decisive and clear strategy, teambuilding and employee welfare.
Entrants must hold a C-suite executive position
and be employed by the company at the time ofnomination.
To enter this category, please answer the following:• Name, company and position of the entrant, andthe date of taking up this post.
• Entrant’s greatest achievements during thequalifying year? What has been the directconsequence on company performance?
• How have these achievements strengthened thecandidate’s influence within the industry?
• Entrant’s greatest strengths as a leader? How didthese have a bearing on their achievements thisyear?
• What specific previous accomplishments helpedwith this success? For example, previous scientificor management experience.

LICENSING
DEAL OF THE
YEAR
Deals considered here are those that involve thelicensing of a particular drug, project or groupof R&D assets from one company to another for
further development and/ or marketing. (Thiscategory does not include more complex, broad
partnerships between companies, for example
to explore particular therapeutic strategies ormechanisms of action.)
The judges will look at all aspects from monetaryand strategic value to the benefits they give to bothsides. To qualify, licensing deals must have beenclosed during the qualifying period of July 1, 2023 June 30, 2024.
To enter this category, please answer the following:• Outline the structure of the deal, giving the namesof the parties involved, the drug candidate(s)concerned, and what rights it covers.
• Monetary value of the deal in up-front andmilestone payments.
• Countries and indications included in the deal
and does it allow any party to enter new markets?
• Strategic value of the licensed product to thelicensee/licensor’s business.
• Please explain how the licensed product was thebest possible candidate to complement the restof the licensee’s pipeline or particular disease
franchise, or how it fit into the licensor’s businessstrategy.

FINANCING
DEAL OF THE
YEAR

PHARMA
CO M PA N Y O F
THE YEAR

This Award seeks to reward successful andcreative fundraising by pharma and biotech
companies in Japan, which are either
privately or publicly owned.

The Pharma Company of the Year Award
honors outstanding achievement bypharmaceutical companies over thequalifying period of July 1, 2023 - June 30,2024. This special award is chosen not by the
independent judging panel but by our own
senior editorial team, based on a variety of
key metrics as below:

The investment can take various forms, including
grants and public-private partnership deals, tofundraising from venture capital and private equity
partners and initial public offerings. The majorityof the new funds should be earmarked for use in
drug discovery and/or company development. The
qualifying period is July 1, 2023 - June 30, 2024.
The basic criterion for this award is the total amountof money raised at one time – for example in a Series
A (or later) funding round or through an IPO – butother factors should be considered as well. For
example:• Did the financing attract a broad range of investor
groups?
• Did investors include groups that do not normallyinvest in pharma/biotech?
• Were any particularly novel financial instruments
or structures used?
• Was the financing/IPO successful despite being
launched in a challenging overall environment?

• Financial performance compared with the same
period in previous fiscal year.
• How the company was able to advance its statedstrategy, looking at most significant achievements
over the year.
• Progress in emerging markets.
• New product launches including line-extensions
and formulations.
• Advances in the drug pipeline, including majorclinical trial reports.
You can nominate your own company but there is
no shortlist and the winner is decided by our senior
editorial team.

LIFETIMEACHIEVEMENT
The winner of this Award will be an
exceptional individual with a consistenthistory of service, above and beyond thecall of duty, throughout their distinguishedcareer in the biotech or pharmaceuticalarena, primarily within industry.
We welcome nominees for consideration forthis Award but the decision lies not with theindependent judging panel but with our senior
editorial team. The winner may be retired or semiretired but will still be active in the industry in some
capacity.
Any entry form should outline, in no more than
1,500 words, what the nominee has accomplishedduring his or her career and say why they are worthyof this Award.
All entry forms must include:• The name of the nominee.
• The job title of the nominee (if applicable).
• The company name (if applicable).
• Your contact details.
• The contact details of the nominee.
You can submit nominations for this award but
there is no shortlist and the winner is decided by our
senior editorial team.

JUDGING
The Citeline Japan Awards will be judged by a panelof industry experts within academia and business,with extensive experience in Japan. Each of the judges
brings a wealth of specialist knowledge, experienceand expertise, carefully selected for their credibility
and objectivity.
The Judging Panel is independent and considers entries objectively;
each category is reviewed by at least three judges. The judges score eachentry against the listed criteria for the category. The awards team collate
the scores to determine which entries are included in the shortlist, andthe ultimate winner.
The chair of the Judging Panel reserves the right to cast any deciding
vote, should the need arise. The judges’ decision is final - neither theorganizers, nor the Judging Panel, will enter into any correspondence
about the results. Details of the winners are strictly embargoed until
the Awards night, but details of all the shortlisted entries will be listed
on www.citeline.com/awards/citelinejapanawards

USEFUL TIPS
FOR A WINNING
ENTRY:
Read the entry details and judging criteria
carefully for each category before starting yoursubmission.
Write your entry specifically for the category inquestion, check the nomination is in the correct
category and would not stand a better chanceof winning in a different category.
Do not exceed the word limit. Entries should
be 1,500 words or less and there should be no
supporting material.
Ensure the activities included were undertaken
between the date parameters, July 1, 2023 June 30, 2024
Ensure each entry meets the specific criteria for
its category.
Ensure you have answered each entry question
under a separate heading in your submission.
Plan ahead to ensure it’s submitted in plenty oftime so that, should it be incomplete, there will
still be time to correct and re-submit it before
the closing date of Monday, July 15, 2024.

JUDGING PANEL
Steve Engen

Mitsuru Miyata

CEO, Renexes LLC, ex-President,
Mundipharma Japan and Solasia Pharma

CEO, Miyata Institute ofTechnologies/President,
Healthcare Innovation

Dr Shoichiro Hamano

Fumiyoshi Sakai

CEO, Hamano International

Japan Healthcare Strategist, Global
Research Division, UBS Securities Japan
Co., LTD

Thomas Jonsson

Managing Director
Zinagi Consulting

Dr Shingo Kano

Professor, University of Tokyo/Graduate
School of Frontier Sciences

Dr Noboru Yamamoto

Deputy Director of the National Cancer
Center Hospital, director, Department ofExperimental Therapeutics and ClinicalResearch Support Office

Kazumi Fujikawa

Dr Keiji Hirai

Former Representative Director andPresident & CEO of KYORIN Pharmaceutical,
Program Officer of AMEDDr Toshio Miyata

Professor, Faculty of Science and Engineering,
Waseda University, and the Waseda University
Center for Advanced Biomedical Sciences

Dr Hiroyuki Sakamaki

President, Ph. D. (School of Medicine), MBA
Pharma Policy Planning PCubed

Jiro Fujiyaso

Director, Head of Pharmaceuticals /HealthCare Industrial Research Division,
SMBC Nikko Sercurities Inc.

Corporate advisor of Seed
Planning, the representative of
HMIC and Ryu no Senaka

Aya Kubota

Editor-in-Chief, Nikkei Biotechnology &Business, Nikkei Business Publications,Inc

Tim Kendall

Business Development and Licensing
Consultant

HOW TO ENTER
The Citeline Japan Awards are open to pharmaor biotech organizations based in Japan (orthose primarily doing business in Japan).
Entries are free of charge.

1

2

3

Select your category.

Complete the downloadable entry form,
explaining in 1,500 words or less why yourorganization should be recognized for its
performance. Please refer to the category
criteria as a guide.

Email your completed PDF entry form
to the Awards team. You will thenreceive a confirmation email from oneof the team.

Entry deadline: Monday, July 15, 2024
www.citeline.com/awards/citelinejapanawards

Entry inquiries
yojiro.terauchi@citeline.com
General inquiries:
natalia.kay@citeline.com

FAQs
Q. How do I enter?
A. Please take your time to read the entry guidelines
and category criteria and decide which category ismost applicable to your organization. Download
a PDF entry form from www.citeline.com/awards/
citelinejapanawards. Answer the questions and criteria
relevant to your chosen category. Once completed,please email your completed PDF entry form to theAwards team before Monday, July 15, 2024.
Q. How much does it cost to enter?
A. Citeline Japan Awards are free to enter.
Q. When is the entry deadline?
A. Entries are accepted until Monday, July 15, 2024.
Q. I am not sure which category is applicable?
A. If you are unsure which category is most suitablefor your organization, please contact natalia.kay@
citeline.com or yojiro.terauchi@citeline.com for further
assistance.
Q. Is it possible to enter the same submission into
more than one category?
A. Where appropriate, we do encourage organizations toenter more than one category. Please ensure you review
the category criteria and tailor your entry accordingly.
Q. I am a sponsor of the Awards, am I still able to enter?
A. Sponsors are very welcome to enter the Awards,
however, they are unable to enter the category they
are sponsoring.

Q. How will I know whether my entry has been
received?
A. Once your entry has been submitted, your organization
will be acknowledged by an email. Our Awards teamwill also be in touch after the entry deadline. If you
have any questions or concerns, please contact Natalia
Kay at natalia.kay@citeline.com
Q. How will I know if my submission has beensuccessful?
A. Following the judging process, all organizations will be
notified by email. Finalists will be announced on the
Citeline Pharma Intelligence Japan Awards website:www.citeline.com/awards/citelinejapanawards
Q. What happens if I win?
A. All winners will be announced at the Awards ceremony.
Each winner will receive a trophy and certificate ofrecognition, as well as a press release and winner logos
for use on social media, email signatures and theirwinners photo (if present at the awards).
Q. How do I get tickets for the event?
A. Please contact Casey Burwell, Global Sales Manager
E: casey.burwell@citeline.com for further information.
Q. What other ways can my organization be involved
with the Awards?
A. There are a number of sponsorship opportunities
available. Please contact Casey Burwell, Global SalesManager E: casey.burwell@citeline.com for further
information.

Disclaimer: Photos from the awards will be using for marketing purposes. By attending the awards, you agree to your picture being taken and used by Citeline.

THE RULES

CONFIDENTIALITY• All entries must be written in Japanese or
English.

• Citeline, organizer of the Citeline Japan
Awards, recognizes and respects thesensitive nature of the information
submitted in the entries. We ensure that thisrecognition is shared by our Judging Paneland therefore require each judge to sign aconfidentiality agreement before they areappointed.

• All entries must be submitted by a PDF
entry form, which can be downloaded onwww.citeline.com/awards/
citelinejapanawards• Once your PDF entry form has been
completed, it needs to be emailed to theAwards team.
• Limit your entry to 1,500 words.
• All entries must be accompanied by a 250word summary of the entry as you would likeit to appear on all publicity material (this isin addition to the 1,500-word entry). Please
do not include confidential material in your250-word summary. We reserve the right toamend your summary if needed.
• All entries must be based on activities
undertaken between July 1, 2023 - June 30,
2024.
• Your organization may enter more than one
category, provided that each entry has been
specifically written to address the relevant
criteria and is accompanied by a separatesummary.

• Entries are not disclosed or discussed
outside the judging process.
• Once an entry is shortlisted, extracts fromthe entry summary only will be sourced forinclusion in the Awards ceremony and any
subsequent editorial coverage.
• Please ensure your entry summary contains
no confidential or sensitive information. The
Judging Panel for each Award is selected to
avoid any conflict of interest.
• In addition to the judges, a very limited
number of administrative staff in Japanand the UK will handle the entry forms foradministrative purposes. By this statement,these administrative staff also agree to theconfidentiality agreement.

CITELINE JAPANTUESDAY, OCTOBER 22, 2024
PA L AC E H OT E L , TO K Y O

ENTRY AND GENERALINQUIRIES:Natalia Kay
Senior Events Manager
E: natalia.kay@citeline.com

Yojiro Terauchi
Senior Marketing Manager
E: Yojiro.Terauchi@citeline.com

SPONSORSHIP AND
AT T E N D A N C E I N Q U I R I E S :Casey Burwell
Global Sales Manager
E: casey.burwell@citeline.com

www.citeline.com/awards/CitelineJapanAwards

T
OJ
KA
YP
OA
N